Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
3.8
2.1
Journals
Children
Special Issues
Pediatric Inflammatory Bowel Disease: Update on Treatment and Therapeutic Endpoints
share announcement

Pediatric Inflammatory Bowel Disease: Update on Treatment and Therapeutic Endpoints

A special issue of Children (ISSN 2227-9067). This special issue belongs to the section "Pediatric Gastroenterology and Nutrition".

Deadline for manuscript submissions: closed (20 July 2025) | Viewed by 1409

Special Issue Editors

Dr. Jonathan Moses

E-Mail Website
Guest Editor
Division of Gastroenterology, Hepatology & Nutrition, Stanford Medicine Children’s Health, Palo Alto, CA, USA
Interests: pediatric inflammatory bowel disease; clinical research; quality improvement
Dr. Ross Maltz

E-Mail Website
Guest Editor
Division of Gastroenterology, Hepatology & Nutrition, Nationwide Children’s Hospital, Columbus, OH, USA
Interests: pediatric inflammatory bowel disease; clinical research; biosimilars

Special Issue Information

Dear Colleagues,

The field of inflammatory bowel disease (IBD) has moved at a rapid pace over the last few years. Areas of advancement have included new knowledge of the factors associated with the genetic predisposition, environmental triggers, and immune system dysregulation associated with IBD, along with advancement of the medical armaments for the treatment of IBD. In addition, the evidence-based development of treatment goals in the clinical care of patients has been established and includes clinical, biochemical, endoscopic and radiologic endpoints.

This Special Issue of Children will focus on pediatric IBD, providing updates on newer therapeutic agents available for achieving treatment goals and up-to-date information on monitoring strategies in clinical care, including endoscopic scoring and the use of intestinal ultrasound.

Dr. Jonathan Moses
Dr. Ross Maltz
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Children is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • pediatrics
  • inflammatory bowel disease
  • biological products
  • drug monitoring
  • endoscopy
  • ultrasonography

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

13 pages, 1732 KiB  
Article
Clinical and Phenotypic Characteristics of Early-Onset Inflammatory Bowel Disease: A Five-Year Observational Study
by Ivan S. Samolygo, Marina A. Manina, Ekaterina A. Yablokova, Pavel A. Stribul, Alexander V. Novikov, Anton S. Antishin, Albina S. Pestova, Alexander S. Tertychnyy, Daniel Munblit and Svetlana I. Erdes
Children 2025, 12(7), 952; https://doi.org/10.3390/children12070952 - 18 Jul 2025
Viewed by 317
Abstract
Background: Inflammatory bowel diseases with an early-onset form (EO-IBDs) make up a special disease group with certain clinical and phenotypic characteristics. This article discusses the features of such early onset in a group of children, based on five years of monitoring a registry [...] Read more.
Background: Inflammatory bowel diseases with an early-onset form (EO-IBDs) make up a special disease group with certain clinical and phenotypic characteristics. This article discusses the features of such early onset in a group of children, based on five years of monitoring a registry of children with IBD from a specialized center. Methods: This retrospective single-center cohort study included pediatric patients diagnosed with EO-IBD between 2019 and 2024. Clinical, laboratory, and endoscopic data were collected from medical records, including fecal calprotectin, inflammatory markers, disease activity indices, and endoscopic severity scores. Localization was classified according to the Paris system, and histological activity was assessed using the IBD-DCA score. Results: There were 20 patients with ulcerative colitis (UC) and 17 with Crohn’s disease (CD). Clinical activity was moderate or high (p = 0.179). UC was more characterized by diarrhea and rectal bleeding. CD was more often accompanied by abdominal pain, weight loss, and fever. In total, 82.4% of patients with CD had an inflammatory form. UC-like intestinal lesion was typical of both nosologies—L3 64.7% and E4 60% forms in CD and UC, respectively. Morphological activity was moderate for both nosologies (p = 0.54). IBD-U was present in 43.2% of patients. The median time after which it was possible to diagnose UC was 24 weeks (IQR 20–48) and 40 weeks (IQR 30–45.5) for CD (p = 0.56). Conclusions: Our study confirms the presence of characteristic signs of EO-IBD development, such as a frequent family history of IBD, high or moderate clinical activity during diagnosis verification, colon damage, and a high frequency of extraintestinal manifestations. Full article
(This article belongs to the Special Issue Pediatric Inflammatory Bowel Disease: Update on Treatment and Therapeutic Endpoints)
►▼ Show Figures

Graphical abstract

10 pages, 206 KiB  
Article
Intensified Upadacitinib Dosing for Adolescent Patients with Acute Severe Ulcerative Colitis
by Perseus V. Patel, Martina Rigmaiden, Alka Goyal, Rachel Bensen, Dorsey Bass, Jonathan Moses, Michael J. Rosen and Ruben J. Colman
Children 2025, 12(4), 401; https://doi.org/10.3390/children12040401 - 22 Mar 2025
Viewed by 812
Abstract
Background/Objectives: In adolescent patients with ulcerative colitis refractory to anti-tumor necrosis factor (TNF) therapy, episodes of acute severe ulcerative colitis (ASUC) require hospitalization or surgery. Upadacitinib can be a potential colectomy-sparing agent in adult ASUC patients receiving intensified dosing. Methods: This [...] Read more.
Background/Objectives: In adolescent patients with ulcerative colitis refractory to anti-tumor necrosis factor (TNF) therapy, episodes of acute severe ulcerative colitis (ASUC) require hospitalization or surgery. Upadacitinib can be a potential colectomy-sparing agent in adult ASUC patients receiving intensified dosing. Methods: This case series evaluates clinical outcomes of intensified rescue upadacitinib dosing in adolescent patients with ASUC. We included adolescents admitted with anti-TNF refractory ASUC treated with 30 mg twice daily upadacitinib. The primary outcome was the proportion of patients who remained colectomy-free at the most recent follow-up. Results: Five patients (aged 14–18) exhibited varying responses to upadacitinib; 2 responded rapidly, while 3 had partial response. All the patients remained on upadacitinib and were colectomy-free during follow-up (55–203 days). Three (60%) ultimately received dual advanced therapy with ustekinumab and upadacitinib. At most recent follow-up, 60% were in clinical/biochemical remission without corticosteroids. Conclusions: In select cases, intensified upadacitinib may be a potential colectomy-sparing option for adolescent ASUC patients refractory to anti-TNF therapy. Full article
(This article belongs to the Special Issue Pediatric Inflammatory Bowel Disease: Update on Treatment and Therapeutic Endpoints)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop